Colorectal Cancer | Specialty

Dr. Shah on the Difference in Treatment of Left- and Right-Sided Tumors in CRC

May 2nd 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.

Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRC

April 26th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).

Dr. Shah on the Increase of Early-Onset CRC

April 20th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the increase in prevalence of early-onset colorectal cancer (CRC).

Inherited Mutations Play Greater Role in CRC Than Previously Thought

April 20th 2017

Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.

Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial

April 17th 2017

The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.

Marshall Addresses Sidedness Issue in Colorectal Cancer

April 13th 2017

John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.

Expert Discusses Differences Between Early-Onset and Traditional CRC

April 11th 2017

Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.

Dr. Shah on Indications of Early-Onset CRC

April 6th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

Dual HER2 Targeting Effective in Refractory mCRC Subset

April 2nd 2017

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

Experts Raise Awareness for Colorectal Cancer

March 25th 2017

Dr. Kennedy on Importance of SIRFLOX Study in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the importance of the SIRFLOX trial, which explored the efficacy of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres as treatment for patients with liver-metastatic colorectal cancer (CRC) versus standard frontline chemotherapy.

Emerging Data Could Show True Benefit of Y-90 Radioembolization in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Sequencing, Patient Selection Among Challenges in GI Cancers

March 17th 2017

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Dr. O'Neil on Stemness Inhibitors for CRC Treatment

March 17th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of Medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Novel Approaches, Individualization Needed in mCRC

March 16th 2017

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

FDA Review Continues for Pembrolizumab in MSI-H Cancer

March 10th 2017

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

Mutations May Help Explain Sidedness Issue in Colorectal Cancer

March 6th 2017

Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.

Bekaii-Saab Discusses Sequencing and Emerging Combinations in mCRC

March 4th 2017

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Interventional Radiology Improving Outcomes in Liver-Metastatic CRC

March 3rd 2017

Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.

First-Line mCRC Treatment Must Encompass Individualized Approach

March 2nd 2017

Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.